IONS insider trading
HealthcareIONIS PHARMACEUTICALS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About IONIS PHARMACEUTICALS INC
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Company website: www.ionis.com
IONS insider activity at a glance
FilingIQ has scored 1,834 insider transactions for IONS since Jan 5, 2016. The most recent filing in our index is dated May 4, 2026.
Across the full history, 3 open-market purchases
and 639 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IONS insider trades is 63.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest IONS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading IONS
13F funds holding IONS
Frequently asked
- How many insider trades does FilingIQ track for IONS?
- FilingIQ tracks 1,834 Form 4 insider transactions for IONS (IONIS PHARMACEUTICALS INC), covering filings from Jan 5, 2016 onwards. 127 of those were filed in the last 90 days.
- Are IONS insiders net buyers or net sellers?
- Across the full Form 4 history for IONS, 3 transactions (0%) were open-market purchases and 639 (35%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IONS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is IONS in?
- IONIS PHARMACEUTICALS INC (IONS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $13.28B.
Methodology & sources
Every IONS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.